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Abstract: The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated 
kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf. Elevation of these up-stream signals occurs 
frequently in a variety of malignancies and ERK kinases play critical roles in promoting cell proliferation. Therefore, inhibition of MEK-
mediated ERK activation is very appealing in cancer therapy. Consequently, numerous MEK inhibitors have been developed over the 
years. However, clinical trials have yet to produce overwhelming support for using MEK inhibitors in cancer therapy. Although complex 
reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide 
proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy. Recent 
developments may support this alternative possibility. Accumulating evidence now demonstrated that the MEK-ERK pathway 
contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. During DDR, the 
MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division. 
Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation. As a result, cells may continue to proliferate 
in the presence of DNA lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. Alternatively, reduction 
in checkpoint activation may prevent efficient repair of DNA damages, which may cause apoptosis or cell catastrophe, thereby enhancing 
chemotherapy’s efficacy. This review summarizes our current understanding of the participation of the ERK kinases in DDR. 
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1. INTRODUCTION 
DDR guards genome integrity via  sensing DNA lesions, 
activating checkpoints to halt cell cycle progression, and repairing 
DNA damage [1]. This process is initiated and coordinated by two 
apical kinases, ataxia-telangiectasia mutated (ATM) and ATR 
(ATM- and Rad3-related). ATM and ATR subsequently upregulate 
p21
CIP1, an inhibitor of cyclin-dependent kinases (Cdks) [2, 3] and 
activate checkpoint kinases 1/2 (CHK1/2). CHK1/2 then inactivates 
Cdc25C which is required for the activation of Cdk1 and Cdk2 [4]. 
Collectively, the activation of ATM and ATR initiates checkpoints 
to prevent cell cycle progression [1]. 
Consistent with ERK kinases being a major player in promoting 
cell cycle progression [5], ERK1 and ERK2 also contribute to DDR 
[6]. A variety of genotoxic agents have been shown to activate the 
ERK kinases and ERK activity modulates DDR [7]. Consistent with 
the apical roles of ATM and ATR in DDR, DNA damage-induced 
ERK activation has been reported to be a downstream event of 
ATM and ATR [8, 9]. On the other hand, ERK activation also 
facilitates the activation of ATM and ATR [10, 11]. The impact of 
the MEK-ERK pathway on checkpoint activation in DDR is cell 
type dependent [6]. While ERK activity facilitates DNA damage-
induced cell cycle arrest and apoptosis in a several mammalian cell 
lines and Drosophila [12, 7, 13, 9, 14, 15], ERK activation also 
prevents DNA damage-induced apoptosis in myeloma and leukemia 
[16, 17]. In this review, we will briefly discuss the ERK system, 
ATM/ATR-initiated DDR, and experimental evidence showing the 
interplay between ERK and DDR. Finally, we will briefly discuss 
strategies of using MEK inhibitors in cancer therapy. 
2. THE CORE FEATURES OF ATM AND ATR ACTIVA-
TION DURING DDR 
DNA damage response is the critical surveillance mechanism 
that maintains genome integrity and ensures the accurate 
transmission of genetic information between generations in   
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eukaryotic cells. DDR is mediated by three apical PI3 kinase related 
kinases (PIKKs), ATM, ATR, and DNA-PKcs (CS: catalytic 
subunit) [1]. PIKKs possess typical structural features, including 
the FRAP-ATM-TRRAP (FAT), kinase, and C-terminal FAT 
(FATC) domain [18, 19]. In line with these structural features, 
activation of PIKKs share common features, including the 
interactions with specific proteins and the association with unique 
DNA lesions [20].  
ATM activation is induced by double stranded DNA breaks 
(DSBs). In human cells, ATM exists as an inactive dimer, which is 
converted into active monomers in response to DSBs via 
autophosphorylation at serine 1981 (S1981) [21]. This 
autophosphorylation stabilizes the association of ATM with DSBs 
[22]. Accumulating evidence demonstrates that the MRE11-
RAD50-NBS1 (MRN) complex plays a pivotal role in ATM 
signalling. Patients with Nijmegen Breakage Syndrome (NBS) or 
Ataxia-Telangiectasia-like Disorder (ATLK) display similar clinical 
and cellular phenotypes with AT patients, including microcephaly, 
immunodeficiency, being prone to the development of malignancy, 
sensitization to ionizing radiation (IR), genomic instability and 
checkpoint defects following DNA damage. These three diseases 
are caused by mutations in NBS1, MRE11, and ATM, respectively 
[23]. These observations, therefore, provide strong genetic and 
cellular evidence showing that the MRN complex and ATM are 
involved in the same DDR pathway. Biochemically, the MRN 
complex directly interacts with ATM, resulting in ATM being 
recruited to DSBs [24, 25, 26], and converting ATM from inactive 
dimers to active monomers [24, 27]. This association of ATM and 
the MRN complex is mediated by a direct interaction between 
ATM and NBS1 [28]. The association with the MRN complex at 
DSBs activates ATM [27] and ATM subsequently phosphorylates 
numerous targets to coordinate checkpoint activation and DNA 
damage repair [1]. 
While ATR is activated by multiple types of DNA lesions, 
including DSBs, base adducts, crosslinks, and replication stress 
[18]; its activation is primarily mediated by the structure containing 
single-stranded DNA (ssDNA) [29, 30]. Association of ATR with 
replication protein A (RPA)-coated ssDNA is required for ATR 
activation. ATR binds directly to the ATR interacting protein 
(ATRIP). This association does not depend on DNA damage but is Erk1/2 Kinases Facilitate DNA Damage Response  Current Medicinal Chemistry,  2011 Vol. 18, No. 35      5477 
required for the stabilization of both ATR and ATRIP, as 
knockdown of one causes the reduction of the other [31]. ATR 
function depends on ATRIP in human cells and its homologues in 
yeast, Rad26 in Schizosaccharomyces prombe and 
DDC2/LCD1/PIE1 in Saccharomyces cerevisiae. Loss of ATRIP in 
yeast and human cells recapitulate the same phenotypes as loss of 
ATR [31, 32, 33, 34, 35, 36]. ATRIP binds to RPA-coated ssDNA 
and thereby results in the recruitment of ATR to the DNA lesion 
[30, 37, 38]. Although the association of the ATR-ATRIP complex 
with RPA-coated ssDNA is required, it is insufficient to increase 
ATR-derived kinase activity. Biochemical analysis revealed that 
TOPBP1 (topoisomerase-binding protein 1), the mammalian 
homologue of yeast Cut5/Dbp11, significantly enhanced the kinase 
activity of the ATR-ATRIP complex in vitro [39]. In line with the 
RPA-coated ssDNA being the primary structure leading to ATR 
activation; TOPBP1 is recruited to RPA-coated ssDNA independent 
of the ATR-ATRIP complex, and requires the Rad17/RFC 
(replication factor C) and the Rad9-Rad1-Hus1 (9-1-1) complex. 
Rad17/RFC binds to RPA-ssDNA (Fig. 1) [40, 20], which loads the 
9-1-1 complex [41, 42] and subsequently recruits TOPBP1 [43, 44]. 
This recruitment allows TOPBP1 to activate ATR via binding to 
both ATR and ATRIP subunits (Fig. 1) [39, 45]. ATR activation 
coordinates a global cellular response to prevent cell cycle 
progression into mitotic phase (S phase arrest or induction of 
apoptosis) and to initiate DNA damage repair [18]. ATR 
accomplishes these multiple functions by phosphorylation of a 
variety of down-stream targets, including the serine 139 (S139) in 
the SQE motif located on the tail of histone H2AX (H2AX), the 
S15 of p53, and the S345 of CHK1 [1, 46, 47].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). An illustration of ATR activation. 1) The ATR-ATRIP complex 
binds to RPA-ssDNA; 2) Rad17/RFC, 9-1-1, and TOPBP1 are sequentially 
loaded onto RPA-ssDNA; 3) TOPBP1 interacts with the ATR-ATRIP 
complex, resulting in ATR activation. 
3. ERK KINASES PLAY A ROLE IN DDR 
It is well recognized that DDR is intimately linked to cell 
division. One of the major tasks of ATM and ATR activation is to 
initiate checkpoint controls to halt cell cycle progression in order to 
coordinate the repair of DNA lesions [1]. Activation of checkpoints 
leads to the up-regulation of p21
CIP1 and the inactivation of 
CDC25C via activation of CHK1 and CHK2 [48, 1]. These events 
collectively inhibit the kinase activity of Cdk1 and Cdk2, leading to 
cell cycle arrest. Therefore, inhibition of Cdk activity or arrest of 
cell division is a downstream event of ATM and ATR. Recent 
developments, however, demonstrated that cell division contributes 
more to DDR than only being a downstream event. Cdk activity 
promotes the proper activation of ATM and ATR in response to 
DNA damage [49, 50]. This may explain, at least in part, a long-
term observation that malignant cells are more sensitive to 
genotoxic agents than cells in normal tissues [51]. Direct evidence 
supporting this concept was the recent demonstration that directly 
blocking cell division via  loss of CDC25 protected intestinal 
mucosa from damage induced by irinotecan, a commonly used 
chemotherapeutic/genotoxic agent in treating patients with colon 
cancer [52]. Consistent with the theme that the mechanism 
regulating cell proliferation actively engages DDR, ERK1 and 
ERK2 kinases, also contributes to DDR via mechanisms that are 
dependent or independent on p53 as well as lying downstream of 
ATM and ATR or facilitates the activation of ATM and ATR. 
3.1. ERK MAP Kinases 
ERK1 and ERK2 (ERK1/2) kinases belong to the mitogen-
activated protein kinase (MAPK) family and are activated by two 
highly conserved upstream kinases, MEK1/2 (MAPK kinase). In 
addition, MEK1/2 kinases are activated by Raf (MAPK kinase 
kinase) [53, 54]. MEK1/2 activates ERK1/2 kinases through 
phoshorylation of threonine 183 (Thr183) and tyrosine 185 
(Tyr185) at the Thr-Glu-Tyr site [54]. In addition to the Raf and 
MEK upstream kinases, ERK activation is facilitated by scaffolding 
proteins. One such protein is the kinase suppressor of Ras 1 (KSR1) 
which binds to MEK and thereby facilitates ERK activation [53, 55, 
56]. ERK functions in multiple signalling pathways via  the 
phosphorylation of numerous target proteins involved in cell 
proliferation, differentiation, and apoptosis [53, 57, 58]. In addition, 
ERK1 and ERK2 achieve substrate specificity using two 
mechanisms. ERK1 and ERK2 phosphorylates serine/threonine 
(S/T) residues that are immediately followed by a proline (P) (S/T-
P motif) [59, 60]. Many ERK substrates contain one or two docking 
sites to facilitate their association with ERK, thereby enhancing 
their phosphorylation [53, 61]. The consensus docking sites for 
DEJL (docking site for ERK and JNK, LXL) and DEF (docking site 
for ERK, FXFP) are (R/K)2X2-6LXL (X: any residue) [61] and 
FXFP [62, 53], respectively.  
3.2. ERK Modulates DDR in a Cell-Dependent Manner 
Activation of ERK1/2 is commonly observed in multiple cell 
lines by a variety of genotoxic agents. Etoposide (ETOP), 
adriamycin, UV, ionizing radiation (IR), hyroxyurea (HU), and 
mitomycin C (MMC) were shown to activate ERK1/2 in mouse 
embryonic fibroblast (MEFs), NIH3T3, MCF7, H9c2, U87, 
keratinocytes cells, and normal human diploid fibroblasts (IMR90 
and 501T) [7, 13, 63, 64, 9, 8, 65, 66]. Both ETOP and IR induced 
ERK activation reaching a plateau at one hour in MEFs [7, 63]. 
However, cisplatin activated ERK in HeLa, A2780, and HEI-OCI 
auditory cells [12, 67, 68], which was observed at 15 minutes and 
reached a peak at 30 minutes [68]. Activation of ERK was also 
observed in T98G cells in response to cisplatin and UV [69]. In 
addition, BRCA1, which induces the activation of CHK1 and 
WEE1, also activated ERK [70]. Collectively, the kinetics of ERK 
activation induced by a variety of DNA damage reagents are 
regulated by cellular contents during DDR. 
ERK activity also modulates checkpoint activation in a cellular 
context-dependent manner. Inhibition of ERK activation with the 
commonly used MEK inhibitors (PD98059 and U0126) and a 
dominant negative MEK1K97M attenuates ETOP and HU-induced 
G2/M and S phase arrest in several cell lines, including NIH3T3, 
MCF7, MEF, and HCT116 [7, 13, 9]. Consistent with these 
observations, knockdown of either ERK1 or ERK2 compromises 
ETOP and HU-induced G2/M and S phase arrest in MCF7 cells 
[10, 11]. Conversely, enforced activation of ERK1/2 using a 
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constitutively active MEK1Q56P sensitizes S phase checkpoint in 
response to HU [13]. The MEK-ERK pathway constitutes an 
intrinsic component of IR-initiated checkpoint in Drosophila [15]. 
In podocytes, Cyb-9 induces DNA damage, cell cycle arrest, and 
ERK activation and inhibition of ERK activation reduces cell cycle 
arrest [71]. MMC activates ERK in neurons, which promotes 
MMC-induced apoptosis [14]. Consistent with these observations, 
ERK activity also contributes to ETOP-induced apoptosis in 
NIH3T3 cells [7], cisplatin-induced apoptosis in HeLa cells [12, 
72], as well as cisplantin- and UV-induced apoptosis in human 
glioblastoma T98G cells [69]. On the other hand, ERK activation 
was reported to inhibit DNA damage-induced apoptosis in 
myeloma and leukemia cells in response to the Chk1 inhibitor 
UCN-01 and cytarabien (AraC), respectively [16, 17]. In human 
multiple myeloma (MM) cells, an inhibitor of CHK1 induces DNA 
damage, which is accompanied by ERK activation. Inhibition of 
ERK activation sensitizes UCN-01, a Chk1 inhibitor, and induced 
DNA damage and apoptosis in MM cells [16]. Similar observation 
was also reported in acute myelogenous leukemia (AML), NB4, 
and HL60 cells in response to cytarabien (AraC)-induced DNA 
damage [17].  
Additionally, ERK activation also contributes to cell cycle re-
initiation following DNA damage-induced cell cycle arrest. It was 
demonstrated in KSR1 deficient mouse embryonic fibroblasts 
(MEF), IR, UV, and MMC-induced ERK activation were inhibited 
and that re-expression of KSR1 in KSR1
-/- MEFs rescued the 
defects of ERK activation in response to IR, UV, and MMC [63]. 
Detailed analysis of MMC-induced DDR in KSR1
-/- MEFs revealed 
that although MMC induced KSR1
-/- MEFs to undergo G2/M arrest, 
the cells were unable to recover from the arrest. Complementation 
of KSR1
-/- MEFs with wild type KSR1 but not a KSR1 mutant that 
is incapable of binding to ERK enabled the cells to recover from 
MMC-induced G2/M arrest [63]. Collectively, these observations 
demonstrate that ERK activation plays a critical role in the re-entry 
of cell cycle following MMC-induced DNA damage [63]. 
Furthermore, ERK activation mediates adriamycin and ETOP-
induced up-regulation of glucose transporter 3 in HeLa cells [73] as 
well as playing a role in IR-induced activation of NF-B [74]. 
Taken together, a large body of evidence reveals that ERK kinases 
play an important role in DDR. 
While the underlying mechanisms responsible for DNA 
damage-induced ERK activation remain elusive, the accumulating 
evidence indicates that MEK mediates ERK activation in DDR. The 
inhibition of MEK activation with MEK inhibitors (PD98059, 
U0126), a dominant negative MEK1K97M, and MEK siRNA 
inhibited ERK activation that is induced by a variety of genotoxic 
agents [7, 13, 9, 8, 64, 16, 10, 11]. However, whether DNA damage 
activates MEK via Raf remains to be demonstrated.  
While MMC activates ERK in wild type but not p53 deficient 
MEFs [66], ETOP induces ERK activation in wild type and p53
-/- 
MEFs [7]. Additionally, both cisplatin and UV robustly activate 
ERK in human glioblastoma T98G cells lacking functional p53 
[69]. Therefore, while p53 may contributes to DNA damage-
induced ERK activation under certain conditions, p53 function may 
not be required. This will be in line with the observation that at 
least half of human cancers express mutant p53. Consistent with 
ATM being the apical kinase in IR-initiated DDR, it has been 
shown that IR-induced ERK activation in U87 cells is partially 
regulated by ATM [8]. Similar observations were also obtained 
from photolysis-induced DSBs [75]. 
3.3. ERK Kinases Facilitate the Activation of ATM and ATR 
Recent developments have advanced our understanding of 
DNA damage-initiated activation of PIKKs. It is becoming clear 
that the activation of PIKKs is mediated by the association with 
specific DNA structures and proteins, like NBS1 for ATM and 
TOPBP1 for ATR [76, 45, 20]. However, the detailed mechanism 
responsible for ATM and ATR activation in DDR remain largely 
elusive. It is thus intriguing that DNA damage-induced ERK 
activation contributes to the activation of ATM and ATR.  
Cisplatin was reported to robustly activate ERK in human 
ovarian carcinoma A2780 cells. Inhibition of ERK activation using 
PD98059 reduced the phosphorylation of p53 at S15 in response to 
cisplatin [67]. In addition, inhibition of ERK activation with U0126 
reduces doxorubicin-induced p53 S15 phosphorylation in H9c2 
cells [64]. As S15 is not followed by a proline (P), it is thus very 
unlikely that ERK1/2 can directly phosphorylate p53 S15. The S15 
is followed by QE (15-SQE-17) (http://www.uniprot.org/uniprot/ 
P04637). Consistent with the S/T-QE sequence is the well 
demonstrated phosphorylation site for ATM and ATR [1], p53 S15 
is phosphorylated by ATM/ATR in DDR [1]. It is, thus, likely that 
ERK enhances p53 S15 phosphorylation, as reported by Persons et 
al. [67] and Liu et al. [64], via facilitation of the activation of ATM 
and or ATR. This possibility is supported by the observation that 
IR-induced nuclear foci of S1981 phosphorylated ATM was 
significantly reduced in U87 cells when ERK activation was 
inhibited by PD184352, a MEK inhibitor [8]. A similar observation 
was also reported in MCF7 cells. U0126 (one of most commonly 
used MEK inhibitors) compromises IR-induced ATR activation as 
well as the downstream events of ATR, including CHK1 activation, 
CDC25 inactivation, and CDC2 inactivation [9]. Consistent with 
ERK1/2 being the major, if not the sole targets of MEK [53], it was 
recently demonstrated that knockdown of either ERK1 or ERK2 
significantly reduced ATM activation (ATM S1981 
phosphorylation and the nuclear foci of S1981 phosphorylated 
ATM) in response to ETOP, and thereby attenuated 
phosphorylation of the ATM substrates, including the S139 of 
H2AX (H2AX), S15 of p53, and T68 of CHK2. As CHK2 
inactivates CDC25C via  phosphorylation of CDC25C S216, 
resulting in G2/M arrest [46, 3, 4], knockdown of either ERK1 or 
ERK2 reduced ETOP-induced CDC25C S216 phosphorylation and 
significantly compromised ETOP-induced G2/M arrest in MCF7 
cells [10]. 
Hydroxyurea (HU) induces stalled replication forks, which 
primarily activates ATR to initiate the S-phase checkpoints [77]. 
HU activated ERK kinase in MCF7 cells, which facilitated ATR 
activation [13, 11]. Additionally, inhibition of ERK activation by 
using MEK inhibitors (PD98059 and U0126) and a dominant 
negative MEK1K97M reduced ATR nuclear foci, phosphorylation 
of ATR targets [p53 S15 and H2AX S139 (H2AX)], S phase arrest 
in response to HU in NIH3T3, MCF7, MEF, and HCT116 cells 
[13]. The inhibition of ERK activation also attenuated CDC2 
tyrosine (Y) 15 phosphorylation induced by HU [13, 11]. 
Phosphorylation of Y15 inactivates CDC2, whose activity is 
required for mitotic entry [78]. Therefore, inhibition of ERK 
activation may reduce HU-induced S phase arrest by improperly 
facilitating CDC2 activation. Conversely, ectopic expression of a 
constitutively active MEK1Q56P sensitized HU-induced formation 
of the nuclear foci of ATR and H2AX [13]. Furthermore, 
knockdown of either ERK1 or ERK2 reduced HU-induced ATR 
activation, CHK1 S345 phosphorylation, p53 S15 phosphorylation, 
and  H2AX [11]. This was associated with compromising HU-
induced S phase arrest and CDC2 Y15 phosporylation [11]. 
Intriguingly, it was observed that knockdown of either ERK1 or 
ERK2 resulted in a significant accumulation of ATR in the 
nucleolus when cells were treated with HU. DNA damage was 
reported to induce protein trafficking in to and out of the nucleolus, 
thereby regulating DDR [79]. In general, proteins with functions in 
promoting DDR, including p14ARF [80], WRN (Werner Syndrome 
Protein) [81, 82], PARP-1 (Poly(ADP-ribose) polymerase-1) [83], 
and BRCA1 [84], translocate from the nucleoli to nucleoplasm 
upon DNA damage. However, proteins that inhibit DDR, like 
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Therefore, the net result of these protein traffics is to promote DDR. 
It is thus plausible that the observed relocation of ATR to the 
nucleolus in HU-treated ERK1 or ERK2 knockdown cells may 
sequester ATR in the nucleoli. This would be consistent with the 
observation that the reduction of either ERK1 or ERK2 has no 
effect on HU-induced recruitment of RPA60 to ssDNA, indicating 
that ERK kinases may not play a major role in the formation of 
RPA-coated ssDNA [11]. Taken together, accumulating evidence 
demonstrates that ERK1/2 facilitates DNA damage-induced ATR 
activation. 
4. FUTURE PERSPECTIVES IN ERK-FACILITATED DDR 
Research carried out in the last decade gradually consolidated 
the contributions of the MEK-ERK kinases to DDR. While being 
heavily investigated for a long period of time, the underlying 
mechanisms whereby DNA damage activates ATM and ATR, two 
apical kinases in DDR, remain unclear. The ERK kinases may add 
to the missing pieces regarding how DNA lesions activate ATM 
and ATR. ERK kinases facilitate the activation of apical ATM or 
ATR kinases in response to a variety of DNA damages (Fig. 2). In 
the case of ATR, ERK kinases facilitate ATR activation at least in 
part by preventing the accumulation of ATR in the nucleolus (Fig. 
2). While the observations that MEK-ERK kinases facilitate the 
proper activation of ATM and ATR do add to the importance of 
ERK in DDR regulation, the underlying mechanisms remain to be 
determined. Will ERK directly phosphorylate ATM/ATR or 
indirectly phosphorylate other components that are involved in 
ATM/ATR activation? Will these phosphorylations play major 
roles in ATM/ATR activation? The ATM protein contains several 
potential ERK phosphorylation sites (S/T-P) and 2 potential ERK 
docking sites, DEJL domains (1150-RKSVLLTL-1157 and 2302-
KKEQSLAL-2309). These sites match to the consensus sequence 
for the DEJL domain (R/K)2X2-6LXL [61]. The phosphorylation of 
ATR at S428 was reported in DDR [86]. We have shown that HU 
robustly induces ATR S428 phosphorylation and that knockdown 
of ERK1 or ERK2 dramatically reduces this event (Fig. 3). The 
kinases that phosphorylate S428 and the impact of this event on 
ATR function remain unknown. However, S428 is followed by a 
proline (P) (DGISPKRRR), a site that matches the substrate 
specificity of ERK kinases [59]. Additionally, human ATR contains 
a candidate DEF motif, 983-FDFP-985. This site matches the 
consensus of the DEF ERK docking site FXFP [62, 53]. It is thus a 
possibility that ERK may phosphorylate ATR at S428. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A model illustrating ERK-facilitated activation of ATM and ATR 
during DDR. 1) DNA lesions lead to activation of ATM, ATR, and ERK; 2) 
ERK facilitates ATM activation; 3) ERK executes the proper ATR 
activation at least in part by ensuring ATR stay in the nucleoplasm.  
5. OPTIMIZATION OF MEK INHIBITORS INVOLVED IN 
CANCER THERAPY 
Ras and Raf [54], ERK kinases are commonly activated 
abnormally in most human cancers due to the converging site in 
transmitting signals derived from growth factors. The amplification 
of upstream growth factor receptors takes place frequently in 
cancer, including the epidermal growth factor receptor (EGFR) in 
solid tumors [87] and BCR-ABL [fusion of the Abl1 oncogene gene 
on chromosome 9 to the BCR (breakpoint cluster region) gene on 
chromosome 22] in chronic myeloid leukemia (CML) [88]. 
Additionally, the amplification of the ras oncogene is detected in 
approximately 30% of human cancers [89]. Mutations leading to 
the activation of BRAF (the B isoform of RAF) were detected in 
27-70% of melanoma, 36-53% of papillary thyroid cancer, 5-22% 
of colorectal cancer, and 30% of ovarian cancer [90]. In line with 
abnormal activation of the ERK kinases being one of the common 
events in human cancers, ERK kinases are well regarded to drive 
cancerous cell proliferation and promote other oncogenic events, 
including survival and angiogenesis [91, 92]. Therefore, inhibition 
of MEK-mediated ERK activation may be an effective option in 
cancer therapy. Indeed, several highly specific MEK inhibitors have 
been developed, including PD184352/CI-1040 (Pfizer), PD0325901 
(Pfizer), AZD6244 (ARRY-142886 or Selumetinib) (Astra Zeneca) 
and RDEA119 (Ardea Biosciences) [93]. While these small 
molecule MEK inhibitors are highly specific and effective in 
preclinical settings, they are, however, not effective in clinical trials 
on a variety of tumors. PD184352, the first MEK inhibitor entering 
clinical trials, failed to show encouraging results when treating 
patients with advanced non-small cell lung, breast, colon, and 
pancreatic cancer [94]. PD0325901 also did not produce 
overwhelming positive outcomes in clinical trials on patients with 
breast, colon, melanoma, and non-small cell lung cancer (NSCLC) 
[95, 96]. This was also the situation for a newly developed MEK 
inhibitor AZD6244 when examined in clinical trials on melanoma 
and NSCLC [97, 98]. While better designed clinical trials on 
selected patients with tumors that are dictated to ERK activation 
caused by BRAF or KRAS activation [99, 100], might have yielded 
more positive outcomes, it is uncertain how the potential positive 
results might be. This is because 1) in clinical trials on melanoma, 
only 12% of tumors with BRAF mutations were partially 
responsive to AZD6244 [97], 2) NSCLCs with KRAS mutations 
display heterozygous responses to MEK inhibitors, and 3) a minor 
proportion (21%) of patients having BRAF V600 mutation showed 
responses to the MEK inhibitor GSK1120212 [101, 102]. Taken 
together, clinical trials using a variety of MEK inhibitors were 
unable to produce outcomes that are proportional to the prevalence 
of ERK activation in human cancers. 
Although there are complex factors that are certainly 
contributing to the lack of success for MEK inhibitors, such as the 
design of clinical trials, limitation of tolerable doses being used, 
and the development of resistance. The role of ERK in 
tumorigenesis may also be a contributing factor. ERK activity is 
widely regarded to provide proliferation signals to cancerous cells, 
the main underlying reason to target ERK activation by using MEK 
inhibitors. However, recent developments have clearly 
demonstrated that ERK kinases play an important role in DNA 
damage response (DDR). This is consistent with the observation 
that activation of the RAF-MEK-ERK pathway is commonly 
associated with chemotherapy and radiotherapy [103] as 
chemotherapeutic drugs commonly induce DNA damage [104]. 
Therefore, applications involving MEK inhibitors in cancer therapy 
should be considered very carefully as maintaining genome 
integrity is a driving force of tumor suppression.  
The contribution of ERK to DDR outlines a scientific 
background for a combinational therapy involving genotoxic drugs 
and MEK inhibitors. As DNA damage-induced ERK activation 
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inhibited DDR-associated apoptosis in myeloma and leukemia [16, 
17], inhibition of ERK activation will be expected to enhance the 
efficacy of genotoxic drugs on these cancers. However, for tumors 
not associated with the hematopoietic system, ERK activation 
sensitizes DNA damage-induced checkpoint activation [7, 9-15, 69, 
71, 72]. Therefore, inhibition of ERK activation in these cancers 
may also enhance the genotoxic effect of chemotherapeutic drugs. 
This may be caused by the accumulation of DNA lesions due to 
impaired checkpoint activation when ERK activation is inhibited. 
This concept is supported by a recent report showing that the MEK 
inhibitor ADZ6244 enhanced radiation-induced reduction of A549-
derived xenograft tumors [105]. However, inhibition of ERK may 
compromise checkpoint activation and thereby allowing cells to 
proliferate in the presence of DNA lesions. This may lead to 
accumulation of mutations and thus contribute to cancer 
progression, which might be attributable to the resistance or the 
inefficiency of MEK inhibitors in cancer therapy. Therefore, a key 
factor in determining a regime of MEK inhibitors and genotoxic 
drugs in treating solid cancers is whether this combinational therapy 
will lead to a catastrophic result due to inefficient repair of DNA 
lesions or continuous cell proliferation in the presence of DNA 
lesions.  
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